M&A Deal Summary

Akorn Acquires Xopenex Inhalation Solution

On September 30, 2014, Akorn acquired medical products company Xopenex Inhalation Solution from Sunovion Pharmaceuticals. for 45M USD

Acquisition Highlights
  • This is Akorn’s 2nd transaction in the Medical Products sector.
  • This is Akorn’s 3rd largest (disclosed) transaction.
  • This is Akorn’s 5th transaction in the United States.

M&A Deal Summary
Date 2014-09-30
Target Xopenex Inhalation Solution
Sector Medical Products
Buyer(s) Akorn
Sellers(s) Sunovion Pharmaceuticals.
Deal Type Divestiture
Deal Value 45M USD

Target

Xopenex Inhalation Solution

United States
Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Search 200,291 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Akorn

Lake Forest, Illinois, United States
Category Company
Founded 1971
Sector Life Science
Employees1,972
Revenue 1.1B USD (2016)
DESCRIPTION

Akorn, Inc. is a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the United States and across the globe. Akorn, Inc. was founded in 1971 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 5 of 5
Sector (Medical Products) 2 of 2
Type (Divestiture) 1 of 1
Country (United States) 5 of 5
Year (2014) 2 of 2
Size (of disclosed) 3 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-08-12 VersaPharm

Marietta, Georgia, United States

VersaPharm is a generic pharmaceuticals company serving niche markets. VersaPharm has commercialized and developed generic products aimed at treating tuberculosis and other infectious diseases, bleeding disorders, and diseases of the central nervous system.

Buy $440M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-10-24 Aciex Therapeutics

Boston, Massachusetts, United States

Aciex Therapeutics, Inc. is an ophthalmic pharmaceutical company centered on developing first in class products to treat ocular diseases.

Sell $120M

Seller(S) 1

SELLER

Sunovion Pharmaceuticals.

Marlborough, Massachusetts, United States
Category Company
Founded 1984
Sector Life Science
Employees2,100
Revenue 1.3B USD (2008)
DESCRIPTION

Sunovion is a pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the central nervous system (CNS) and respiratory disease areas and improve the lives of patients and their families.

DEAL STATS #
Overall 1 of 2
Sector (Medical Products) 1 of 1
Type (Divestiture) 1 of 2
Country (United States) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-09-05 Elevation Pharmaceuticals

San Diego, California, United States

Elevation Pharmaceuticals, founded in 2008 by two highly experienced respiratory drug development executives, is focused on developing improved aerosol therapies for patients with COPD who require nebulizer delivery of their medicines, generally those who are sicker and older.

Buy $430M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2016-08-31 Cynapsus Therapeutics

Toronto, Ontario, Canada

Cynapsus Therapeutics, Inc. is a specialty central nervous system pharmaceutical company that has been developing a fast-acting, easy-to-use, sublingual thin film for the on-demand management of debilitating OFF episodes associated with PD.

Buy $624M
Mergr

Product

Company

Legal